A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT01900652
- Phase
- PHASE2
- Status
- Completed
Conditions
- Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Emibetuzumab — DRUGAdministered IV
- Erlotinib — DRUGAdministered Orally
Study Details
The primary purpose of this study is to evaluate the efficacy of the study drug known as LY2875358, administered alone or in combination with a second drug named Erlotinib, in participants affected by a defined type of lung cancer (MET biomarker diagnostic positive Non-Small-Cell Lung Cancer) that experienced a disease progression during the most recent treatment with Erlotinib.
Key Dates
- First listed
- Jul 16, 2013
- Start date
- Aug 31, 2013
- Status verified
- Sep 2019
- Primary completion
- Feb 28, 2015
- Completion
- Mar 31, 2016
Study Design
- Enrollment
- 111 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Emibetuzumab plus Erlotinib750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
- Experimental: Arm B: Emibetuzumab750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
Primary Outcome Measure
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) [ Time Frame: Baseline to Objective Disease Progression or Start of New Anticancer Therapy (Up to 15 Months) ]
Locations (32)
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham· Birmingham, ALUniversity of California - San Diego· La Jolla, CAFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Los Angeles, CAUniversity of California, Davis - Health Systems· Sacramento, CAUCLA· Santa Monica, CAUniversity of Colorado Health Sciences Center· Aurora, CO
Related Studies
- Molecular Analysis of Thoracic MalignanciesEnrolling By Invitation · Stanford University · Stanford, California
- Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.Recruiting · University of Colorado, Denver · Aurora, Colorado
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona